JP5778675B2 - 治療性アリール−アミド−アリール化合物およびその使用 - Google Patents

治療性アリール−アミド−アリール化合物およびその使用 Download PDF

Info

Publication number
JP5778675B2
JP5778675B2 JP2012526118A JP2012526118A JP5778675B2 JP 5778675 B2 JP5778675 B2 JP 5778675B2 JP 2012526118 A JP2012526118 A JP 2012526118A JP 2012526118 A JP2012526118 A JP 2012526118A JP 5778675 B2 JP5778675 B2 JP 5778675B2
Authority
JP
Japan
Prior art keywords
independently
aaa
acid
methyl
chloro
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2012526118A
Other languages
English (en)
Japanese (ja)
Other versions
JP2013503819A (ja
JP2013503819A5 (https=
Inventor
パトリック トーマス コーコラン，ジョナサン
パトリック トーマス コーコラン，ジョナサン
バレット カリンドジャン，サーキス
バレット カリンドジャン，サーキス
デヴィッド ボースウィック，アラン
デヴィッド ボースウィック，アラン
レジナルド アダムス，デヴィッド
レジナルド アダムス，デヴィッド
テレサ ブラウン，ジェーン
テレサ ブラウン，ジェーン
シアーズ，ジェイソン，ジョン
ミシェル エイドリアン タディ，デヴィッド
ミシェル エイドリアン タディ，デヴィッド
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Kings College London
Original Assignee
Kings College London
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kings College London filed Critical Kings College London
Publication of JP2013503819A publication Critical patent/JP2013503819A/ja
Publication of JP2013503819A5 publication Critical patent/JP2013503819A5/ja
Application granted granted Critical
Publication of JP5778675B2 publication Critical patent/JP5778675B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C235/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms
    • C07C235/70—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups and doubly-bound oxygen atoms bound to the same carbon skeleton
    • C07C235/84—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups and doubly-bound oxygen atoms bound to the same carbon skeleton with the carbon atom of at least one of the carboxamide groups bound to a carbon atom of a six-membered aromatic ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C233/00—Carboxylic acid amides
    • C07C233/64—Carboxylic acid amides having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings
    • C07C233/67—Carboxylic acid amides having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by singly-bound oxygen atoms
    • C07C233/75—Carboxylic acid amides having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by singly-bound oxygen atoms with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by a carbon atom of a six-membered aromatic ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C235/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms
    • C07C235/42—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings and singly-bound oxygen atoms bound to the same carbon skeleton
    • C07C235/44—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings and singly-bound oxygen atoms bound to the same carbon skeleton with carbon atoms of carboxamide groups and singly-bound oxygen atoms bound to carbon atoms of the same non-condensed six-membered aromatic ring
    • C07C235/56—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings and singly-bound oxygen atoms bound to the same carbon skeleton with carbon atoms of carboxamide groups and singly-bound oxygen atoms bound to carbon atoms of the same non-condensed six-membered aromatic ring having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a six-membered aromatic ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C237/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups
    • C07C237/28—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atom of at least one of the carboxamide groups bound to a carbon atom of a non-condensed six-membered aromatic ring of the carbon skeleton
    • C07C237/42—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atom of at least one of the carboxamide groups bound to a carbon atom of a non-condensed six-membered aromatic ring of the carbon skeleton having nitrogen atoms of amino groups bound to the carbon skeleton of the acid part, further acylated
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D213/28—Radicals substituted by singly-bound oxygen or sulphur atoms
    • C07D213/30—Oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/79—Acids; Esters
    • C07D213/80—Acids; Esters in position 3
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/81—Amides; Imides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D237/00—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings
    • C07D237/02—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings
    • C07D237/06—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D237/10—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D237/24—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/02—Systems containing only non-condensed rings with a three-membered ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/04—Systems containing only non-condensed rings with a four-membered ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/06—Systems containing only non-condensed rings with a five-membered ring
    • C07C2601/08—Systems containing only non-condensed rings with a five-membered ring the ring being saturated
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/12—Systems containing only non-condensed rings with a six-membered ring
    • C07C2601/14—The ring being saturated

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Hydrogenated Pyridines (AREA)
  • Pyridine Compounds (AREA)
JP2012526118A 2009-09-01 2010-09-01 治療性アリール−アミド−アリール化合物およびその使用 Expired - Fee Related JP5778675B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB0915196.0A GB0915196D0 (en) 2009-09-01 2009-09-01 Therapeutic compounds and their use
GB0915196.0 2009-09-01
PCT/GB2010/001650 WO2011027106A1 (en) 2009-09-01 2010-09-01 Therapeutic aryl-am i do-aryl compounds and their use

Publications (3)

Publication Number Publication Date
JP2013503819A JP2013503819A (ja) 2013-02-04
JP2013503819A5 JP2013503819A5 (https=) 2013-08-22
JP5778675B2 true JP5778675B2 (ja) 2015-09-16

Family

ID=41202973

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2012526118A Expired - Fee Related JP5778675B2 (ja) 2009-09-01 2010-09-01 治療性アリール−アミド−アリール化合物およびその使用

Country Status (15)

Country Link
US (2) US20120149737A1 (https=)
EP (1) EP2473479A1 (https=)
JP (1) JP5778675B2 (https=)
CN (1) CN102639487A (https=)
AU (1) AU2010291056B2 (https=)
BR (1) BR112012004173A2 (https=)
CA (1) CA2771097C (https=)
GB (1) GB0915196D0 (https=)
IL (1) IL218137A (https=)
MX (1) MX2012002481A (https=)
NZ (1) NZ598331A (https=)
RU (1) RU2012108173A (https=)
SG (1) SG178480A1 (https=)
WO (1) WO2011027106A1 (https=)
ZA (1) ZA201201287B (https=)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0915196D0 (en) 2009-09-01 2009-10-07 King S College London Therapeutic compounds and their use
WO2012125749A2 (en) * 2011-03-14 2012-09-20 Io Therapeutics, Inc. INFLAMMATION AND AUTOIMMUNE DISORDER TREATMENT USING RARα SELECTIVE AGONISTS
CN102727475B (zh) * 2012-06-14 2014-05-07 合肥博太医药生物技术发展有限公司 视黄酸及其衍生物在制备防治老年痴呆药物中的应用
JP6596090B2 (ja) * 2014-12-17 2019-10-23 キングス カレッジ ロンドン レチノイン酸受容体ベータ（ＲＡＲβ）アゴニストとしてのビシクロヘテロアリール−ヘテロアリール−安息香酸化合物
EP3267969A1 (en) * 2015-03-09 2018-01-17 King's College London Combination therapy with rar alpha agonists for enhancing th1 response
WO2017066428A1 (en) 2015-10-13 2017-04-20 H. Lee Moffitt Cancer Center & Research Institute, Inc. Brd4-kinase inhibitors as cancer therapeutics
WO2017174999A1 (en) * 2016-04-07 2017-10-12 High Force Research Limited Synthetic retinoids for use in rar mediated conditions
CN107459519A (zh) 2016-06-06 2017-12-12 上海艾力斯医药科技有限公司 稠合嘧啶哌啶环衍生物及其制备方法和应用
GB201900687D0 (en) 2019-01-17 2019-03-06 King S College London Immunotherapeutic methods and compositions
AU2019400930A1 (en) 2018-12-19 2021-07-01 King's College London Immunotherapeutic methods and compositions
CA3128032A1 (en) 2019-01-29 2020-08-06 The Johns Hopkins University Small molecule neutral sphingomyelinase 2 (nsmase2) inhibitors
WO2020263960A1 (en) * 2019-06-28 2020-12-30 Carl Wagner Compositions comprising a retinoid x receptor (rxr) agonist, a retinoic acid receptor (rar) agonist, or a dual rxr/rar agonist
JP2026500298A (ja) 2022-12-15 2026-01-06 シンジェンタ クロップ プロテクション アクチェンゲゼルシャフト 殺有害生物剤として有用である新規な二環式カルボキサミド化合物

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2260118C2 (de) 1972-12-08 1982-06-03 Bayer Ag, 5090 Leverkusen Penicilline sowie ihre Verwendung als Arzneimittel
DE3580134D1 (de) 1984-07-07 1990-11-22 Shudo Koichi Prof Dr Chem Benzoesaeurederivate.
JPS61233678A (ja) 1985-04-09 1986-10-17 Maruko Seiyaku Kk ベンジルピペラジン誘導体
JPS62215581A (ja) 1986-03-18 1987-09-22 Koichi Shiyudo フラボンカルボン酸誘導体
US4808631A (en) 1986-11-07 1989-02-28 Hoffmann-La Roche Inc. Aromatic acid derivatives
US4992468A (en) 1989-07-26 1991-02-12 Allergan, Inc. Phenylethenyl compounds having retinoid-like activity
ZA911101B (en) * 1990-02-14 1991-11-27 Chugai Pharmaceutical Co Ltd Inhibition of modified ldl products
FR2663850B1 (fr) 1990-07-02 1994-01-14 Gird Galderma Composition pharmaceutique ou cosmetique contenant en association un retinouide et un sterol.
EP0619116A3 (en) 1993-04-05 1994-11-23 Hoechst Japan Use of synthetic retinoids for osteopathy.
US5648385A (en) 1994-01-03 1997-07-15 Bristol-Myers Squibb Co. Retinoid-like compounds
US5849735A (en) 1995-01-17 1998-12-15 American Cyanamid Company Tricyclic benzazepine vasopressin antagonists
US5559248A (en) 1995-04-05 1996-09-24 Bristol-Myers Squibb Co. Retinoid-like heterocycles
ES2180751T3 (es) 1995-04-10 2003-02-16 Taiho Pharmaceutical Co Ltd Inhibidor de metastasis de cancer.
JP3964478B2 (ja) 1995-06-30 2007-08-22 エーザイ・アール・アンド・ディー・マネジメント株式会社 ヘテロ環含有カルボン酸誘導体及びそれを含有する医薬
FR2739777B1 (fr) 1995-10-11 1997-11-14 Cird Galderma Ligand antagoniste rar-gamma ou agoniste rar-alpha en tant qu'inhibiteur d'apoptose
US5663357A (en) * 1995-11-22 1997-09-02 Allergan Substituted heteroarylamides having retinoid-like biological activity
HUP0102470A3 (en) 1998-07-01 2002-05-28 Takeda Chemical Industries Ltd 1,3-azole derivatives as retinoid-associated receptor regulators and their use
US6245884B1 (en) 1998-10-16 2001-06-12 Vivian Y. H. Hook Secretases related to alzheimer's dementia
PL198852B1 (pl) 1998-10-22 2008-07-31 Neurosearch As Podstawione pochodne fenylu, kompozycja farmaceutyczna je zawierająca oraz ich zastosowanie
TW400614B (en) 1998-11-06 2000-08-01 United Microelectronics Corp The manufacture method of Shallow Trench Isolation(STI)
US6897304B2 (en) 2000-09-22 2005-05-24 Zenyaku Kogyo Kabushiki Kaisha Cephem compounds and ESBL-detecting reagents containing the same
CA2432825A1 (en) 2000-12-15 2002-06-20 Emory University Nonpeptide agonists and antagonists of vasopressin receptors
GB0103998D0 (en) 2001-02-19 2001-04-04 King S College London Method
US7105566B2 (en) * 2002-10-22 2006-09-12 Allergan, Inc. Methods of treatment during vascular procedures
US8367822B2 (en) 2003-09-22 2013-02-05 Enzo Therapeutics, Inc. Compositions and methods for bone formation and remodeling
KR100921173B1 (ko) * 2007-11-14 2009-10-13 (주)아모레퍼시픽 피부 내에서 히알루론산 생합성을 촉진시키는3,4,5-트리메톡시벤즈 아미드 유도체 화합물, 그 제조방법및 이를 함유하는 화장료 조성물
EP2415755A4 (en) 2009-03-31 2012-09-19 Renascience Co Ltd INHIBITOR AGENT OF PLASMINOGEN ACTIVATOR INHIBITOR 1
GB0915196D0 (en) 2009-09-01 2009-10-07 King S College London Therapeutic compounds and their use
WO2012058378A1 (en) 2010-10-29 2012-05-03 Romark Laboratories L.C. Pharmaceutical compositions and methods of use of salicylanilides for treatment of hepatitis viruses

Also Published As

Publication number Publication date
AU2010291056A1 (en) 2012-03-15
IL218137A (en) 2016-06-30
US20120149737A1 (en) 2012-06-14
GB0915196D0 (en) 2009-10-07
ZA201201287B (en) 2013-05-29
CA2771097C (en) 2019-01-15
CA2771097A1 (en) 2011-03-10
EP2473479A1 (en) 2012-07-11
CN102639487A (zh) 2012-08-15
RU2012108173A (ru) 2013-10-10
SG178480A1 (en) 2012-04-27
WO2011027106A1 (en) 2011-03-10
MX2012002481A (es) 2012-03-26
JP2013503819A (ja) 2013-02-04
US9447028B2 (en) 2016-09-20
AU2010291056B2 (en) 2016-01-28
IL218137A0 (en) 2012-06-28
NZ598331A (en) 2013-10-25
BR112012004173A2 (pt) 2017-05-30
US20160039747A1 (en) 2016-02-11

Similar Documents

Publication Publication Date Title
JP5778675B2 (ja) 治療性アリール−アミド−アリール化合物およびその使用
RU2668952C2 (ru) (гетеро)арилциклопропиламины в качестве ингибиторов lsd1
JP6101675B2 (ja) 代謝病の治療用の化合物
RU2681211C2 (ru) (гетеро)арилциклопропиламины в качестве ингибиторов lsd1
RU2663835C2 (ru) Производные тиофена, используемые для лечения сахарного диабета
JPH08512046A (ja) 抗アテローム性動脈硬化症ジアリール化合物
JPH08503925A (ja) 脂肪族−またはヘテロ原子−含有連結基によりアリールまたはヘテロアリールに連結されたフェニル含有化合物
TW201100076A (en) Substituted aminopropionic derivatives as neprilysin inhibitors
JP2004525117A (ja) 置換アミノジカルボン酸誘導体
MXPA06002551A (es) Compuestos de aril o heteroaril amida.
US10752616B2 (en) Bicycloheteroaryl-heteroaryl-benzoic acid compounds as retinoic acid receptor beta (RARβ) agonists
JP2003509401A (ja) 製薬学的性質を有する新規なアミノジカルボン酸誘導体
CN104822661A (zh) 新的5-氨基四氢喹啉-2-羧酸及其用途
JP2005537231A (ja) 新規なグルカゴンアンタゴニスト
TW200901961A (en) Substituted fused-ring compounds for inflammation and immune-related uses
WO2000023407A2 (en) Ureido-thiobutyric acid derivatives as ppar-agonists
TW201443071A (zh) 作爲ｎｅｐ抑制劑之經取代二苯丁酸膦酸衍生物
CN111848461A (zh) Nlrp3炎症小体抑制剂及其制备方法和应用
CN104470886A (zh) 用于治疗代谢疾病的邻-氟取代的化合物
WO1999027965A1 (en) Antihyperlipemic agents
ES2907746T3 (es) Compuestos de amida y uso de los mismos
JP2023530708A (ja) 甲状腺様作用剤
JPS6112907B2 (https=)
CN105008337B (zh) 具有改善的体内功效的作为nep抑制剂的取代的联苯基丁酸衍生物
WO1999021543A1 (en) Amide derivatives

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20121017

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20130705

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20130705

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20140710

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20140722

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20141009

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20141017

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20150121

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20150707

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20150709

R150 Certificate of patent or registration of utility model

Ref document number: 5778675

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

LAPS Cancellation because of no payment of annual fees